MatOrtho announces appointment of Duncan Wilson as Chief Executive Officer
MatOrtho Ltd is delighted to announce the appointment of Duncan Wilson as Chief Executive Officer. He brings extensive experience of the medical device sector, having most recently served for 5 years as Vice President and General Manager UK, Ireland and Nordics for HillRom. During his tenure he oversaw a significant transformation of the business, leading to sustained, profitable growth and a doubling of operating income.
In the 6 years prior, Duncan was Chief Operating Officer and Head of NW Europe and UK MD for Fresenius Medical Care leading significant ‘ahead of market’ revenue growth in multiple markets and was a Board director for several European subsidiaries. Duncan gained insights into orthopaedics as VP/General Manager at Stryker MedSurg Division in EMEA and as the Managing Director of Mantis Surgical in the formative part of his career.
Duncan has a track record of delivering strong sales and profit growth through thorough strategic analysis, development of sales excellence programmes allied to building and leading strong teams.
Founder and Chairman Mike Tuke commented “I am delighted we have been able to secure such an experienced and proven commercial leader for MatOrtho® as we go through the next stage of the company’s life. With new financing and support from Connection Capital we are primed for substantial growth as our new technologies come to market. Duncan will be key to shaping and leading the growth in established markets and opening up new geographies over the coming few years.”
In response, Duncan Wilson said “It’s a great honour to take the CEO role at MatOrtho®. I am really looking forward to taking on the baton from an industry legend such as Mike Tuke and helping him and the team deliver his vision of enabling patients to have the best implants for their conditions across multiple markets. I am excited by the clinical and commercial potential of MatOrtho’s new implant technologies which can make a real difference to the active patient communities for which they were developed.”